July 26, 2021 -- Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.
Molcure's AI platform is based on evolutionary molecular engineering, next-generation sequencing, and laboratory automation technologies. Together, the companies generated potent, binding antibodies to an undisclosed oncology target for Twist's internal pipeline of antibody candidates.
Twist and Molcure attribute the success in part to a technology agreement between the two firms under which they are working to develop new antibody targets, they said.